You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company's adaptive low-resource testing technology requires no instrumentation and limited equipment, making it adaptable to settings without clinical lab infrastructure.
The Euroimmun's Anti-SARS-CoV-2 ELISA test is the first serology test whose results were independently validated by the federal government.
Among the study's aims is determining how rates of SARS-CoV-2 infection differ between healthy children and ones with asthma or other allergic conditions.
The effort is receiving $1.5 billion in funding with up to $500 million set aside for a competition among researchers developing rapid testing technologies.
The charity also announced a partnership with Sage Bionetworks to establish an online repository for biomarker data generated by grant recipients.
The aim will be to establish the performance of serology tests for COVID-19 that are being marketed without FDA review and those seeking Emergency Use Authorization.
Policymakers have touted such tests as key to easing shutdowns, but high specificity will be needed to avoid misinforming people about their infection status.
Healthy adults from across the US with no confirmed history of COVID-19 and no current symptoms are eligible to participate and will be enrolled over the phone.
The Bill & Melinda Gates Foundation will also provide support to winners of the challenge, which may include a grant of up to $500,000.
The company will conduct a clinical study examining the proteins BCL6 and SIRT1 as biomarkers of endometriosis and endometrial receptivity.